Nova Eye Medical Ltd is an Australia-based medical technology company specializing in the development, manufacturing, and commercialization of innovative ophthalmic devices. The company is best known for its proprietary glaucoma treatment technologies, including the iTrack minimally invasive glaucoma surgery (MIGS) device and the Molteno3® glaucoma drainage device, which are used by eye surgeons in over 100 countries. Nova Eye Medical also markets the 2RT ophthalmic laser through its AlphaRET segment, designed for the treatment of retinal diseases such as age-related macular degeneration. The company operates globally, serving both healthcare professionals and patients with advanced solutions aimed at improving clinical outcomes and quality of life. Nova Eye Medical Ltd is listed on the CHI-X Market Australia - Limit Venue, providing investors access to a specialized healthcare equipment and supplies sector company with a focus on ophthalmology.